Clinical Trial Update: Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of MK-2206 in combination with endocrine therapy for hormone receptor-positive metastatic breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• MK-2206 (MK-2206)

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Metastatic Breast Cancer | Phase 2 | Status: WITHDRAWN